5-Amino-1MQ
Also known as: 5-Amino-1-methylquinolinium
5-Amino-1MQ is a small heterocyclic molecule (not a peptide) that acts as a selective, membrane-permeable inhibitor of nicotinamide N-methyltransferase (NNMT). It is under preclinical investigation for obesity and non-alcoholic fatty liver disease. It is not FDA-approved and has not completed human clinical trials; it is commonly tracked alongside peptides because grey-market vendors sell it for metabolic protocols.
Pricing for 5-Amino-1MQ
Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.
COAs for 5-Amino-1MQ
46 third-party tests across 18 vendors. Each card links to the full report.
For
5-Amino-1MQ
by Riptide Wellness· batch RW5MQ-50-1001
For
5-Amino-1MQ
by OROS Research· batch OR-LP5A150-526-B1
For
5-Amino-1MQ
by Ion Peptide· batch 50AM-05042026
For
5-Amino-1MQ
by Ion Peptide· batch 20AM-05042026
For
5-Amino-1MQ
by Real Peptides· batch Yellow Cap
For
5-Amino-1MQ
by Peptide Supply Co.· batch 5AM5004212026
For
5-Amino-1MQ
by Peptide Plugs· batch 112-U-A
For
5-Amino-1MQ
by Amino Club· batch AMQ0001
For
5-Amino-1MQ
by Ion Peptide· batch SAM10-03232026
For
5-Amino-1MQ
by Mile High Compounds· batch AMN-050-MH-01
For
5-Amino-1MQ
by Real Peptides
For
5-Amino-1MQ
by Peptide Supply Co.· batch 5AM1022026
For
5-Amino-1MQ
by Licensed Peptides· batch 5AMINO-01
For
5-Amino-1MQ
by Simple Peptide· batch 5aAMC-02032026
For
5-Amino-1MQ
by Ion Peptide· batch 5AMQ50-01222026
For
5-Amino-1MQ
by Ion Peptide· batch 5AM50-0410826
For
5-Amino-1MQ
by Ion Peptide· batch 5AM10-122825
For
5-Amino-1MQ
by Simple Peptide· batch AM20-12152025-J
For
5-Amino-1MQ
by Ion Peptide· batch 5MQ-12125
For
5-Amino-1MQ
by Simple Peptide· batch AM50-11132025-3
For
5-Amino-1MQ
by Verified Peptides· batch 12-25-0350C
For
5-Amino-1MQ
by Ion Peptide· batch 5A5-1025
For
5-Amino-1MQ
by Ion Peptide· batch 5A-1025
For
5-Amino-1MQ
by Glacier Aminos· batch 5AM5092501
9 citations indexed for 5-Amino-1MQ
review · 2025
Nicotinamide N-Methyltransferase in Cardiovascular Diseases: Metabolic Regulator and Emerging Therapeutic Target
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, arising from complex interactions among metabolic, genetic, and environmental factors. Nicotinamide N-methyltransferase (NNMT) has recently emerged as a key metabolic regulator in CVD pathogenesis.
Study · 2025
Nicotinamide N-Methyltransferase in the Inflammatory Pathogenesis of Graves' Orbitopathy
Purpose Nicotinamide N-methyltransferase (NNMT) has been implicated in inflammatory autoimmune disease pathogenesis, although its pro-inflammatory role in Graves' orbitopathy (GO) is unclear. Therefore, we investigated the influence and mechanisms of NNMT in GO inflammation.
review · 2025
Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets
Hepatocellular carcinoma (HCC), the predominant form of primary liver cancer, remains a global health challenge with limited therapeutic options and high mortality rates.
review · 2024
Biological Functions and Therapeutic Potential of NAD<sup>+</sup> Metabolism in Gynecological Cancers
Nicotinamide adenine dinucleotide (NAD + ) is an important cofactor for both metabolic and signaling pathways, with the dysregulation of NAD + levels acting as a driver for diseases such as neurodegeneration, cancers, and metabolic diseases.
review · 2024
Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome
Metabolic syndrome (MetS) represents a constellation of metabolic abnormalities, typified by obesity, hypertension, hyperglycemia, and hyperlipidemia. It stems from intricate dysregulations in metabolic pathways governing energy and substrate metabolism.
review · 2023
Chromatin and Cancer: Implications of Disrupted Chromatin Organization in Tumorigenesis and Its Diversification
A hallmark of cancers is uncontrolled cell proliferation, frequently associated with an underlying imbalance in gene expression. This transcriptional dysregulation observed in cancers is multifaceted and involves chromosomal rearrangements, chimeric transcription factors, or altered epigenetic marks.